← Back to Search

Novel spectacle lens design

New Glasses for Nearsightedness (CYPRESS Trial)

Salt Lake City, UT
N/A
Waitlist Available
Research Sponsored by SightGlass Vision, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 months

Summary

This trial will test if a new type of glasses can help reduce the progression of juvenile myopia, and if it is safe to use.

See full description
Who is the study for?
This trial is for kids who were in the CYPRESS study and can commit to wearing special glasses for up to 3 years, at least 10 hours a day. They shouldn't have been out of the previous study for over 30 days and must not wear contact lenses during this time. Parents or guardians need to consent.
What is being tested?
The trial tests SightGlass Vision Diffusion Optics Technology (DOT) Spectacles' long-term ability to slow down worsening near-sightedness in children compared with regular glasses, monitored over a period of three years.See study design
What are the potential side effects?
Specific side effects are not listed, but as with any eyewear, there may be discomfort or adjustment issues. The spectacles are non-invasive so significant side effects are unlikely.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Spherical equivalent refraction (SER)
Secondary study objectives
Axial length
SER

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CYPRESS Extension Test ArmExperimental Treatment1 Intervention
Single vision, impact resistant spectacle lenses; CYPRESS Test Arm 1 and CYPRESS Test Arm 2 will move into CYPRESS Extension Test Arm
Group II: CYPRESS Extension Control ArmPlacebo Group1 Intervention
Single vision, impact resistant spectacle lenses; CYPRESS Control Arm remains in control lenses as the CYPRESS Extension Control Arm

Find a Location

Closest Location:William J Bogus, OD, FAAO· Salt Lake City, UT

Who is running the clinical trial?

SightGlass Vision, Inc.Lead Sponsor
10 Previous Clinical Trials
893 Total Patients Enrolled

Media Library

SightGlass Vision Diffusion Optics Technology (DOT) Spectacles (Novel spectacle lens design) Clinical Trial Eligibility Overview. Trial Name: NCT04947735 — N/A
Near-sightedness Research Study Groups: CYPRESS Extension Control Arm, CYPRESS Extension Test Arm
Near-sightedness Clinical Trial 2023: SightGlass Vision Diffusion Optics Technology (DOT) Spectacles Highlights & Side Effects. Trial Name: NCT04947735 — N/A
SightGlass Vision Diffusion Optics Technology (DOT) Spectacles (Novel spectacle lens design) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04947735 — N/A
Near-sightedness Patient Testimony for trial: Trial Name: NCT04947735 — N/A
~4 spots leftby Apr 2025